A new study exploring the investigational therapy, Zorpo-cel, met its primary safety and secondary efficacy endpoints in ...

The U.S. Food and Drug Administration (FDA) issued a complete response letter requesting additional information from ...

Congress has taken the final steps in the FY 2026 budget process, passing legislation that increases funding for lupus programs, including $27 million - the most in history - for lupus programs at the ...

We were joined experts who shared expert insights, practical tips, and personal experiences to empower patients to build ...

Black History Month serves as a reminder to actively amplify Black voices, share stories and raise awareness throughout the year. This month, we’re featuring Danielle Storr, a Black lupus warrior who ...

The U.S. Food and Drug Administration (FDA) has granted Biogen’s investigational drug, litifilimab, Breakthrough Therapy Designation for the treatment of cutaneous lupus erythematosus (CLE).

Our most recent episode of The Expert Series podcast explores the newly released SLE treatment guidelines and how they might affect patient care.

Interested in getting research like this straight to your inbox? Subscribe to our monthly Inside Lupus Research email for all the latest. Discover and match to lupus clinical trials faster with our ...

The Lupus Foundation of America has partnered with Carebox, the leading software platform for clinical trial patient recruitment, to launch the Lupus Clinical Trial Finder, a free platform available ...

The U.S. Food and Drug Administration (FDA) approved Gazyva® to treat adults with lupus nephritis in October 2025. Gazyva targets and removes harmful B cells to help protect the kidneys in people with ...